
WHY THE GENDER AND HEALTH EQUITY COMMITTEE?

Flavia Franconi

Laboratorio Nazionale Medicina e Farmacologia di Genere Del Consorzio Interuniversitario Biostrutture e Biosistemi, Centro Universitario di Studi sulla Medicina di Genere – Università di Ferrara



25 Women data No Women data

Figure 13. Number of articles reporting data on women by year

file:///C:/Users/user/Documents/rev%20farmaci/treatment%2 Oand%20strategies%20for%20women%20with%20cv.pdf

women are treated as 'small



Preclinical studies have been mainly performed in male animals (Beery A & Zucker I. Neurosci Biobehav Rev, 35, 565, 2011).

In vitro experiments, cells do not have a sex (Franconi F et al Int J Cardiol 179 (2015) 514–535





Fig. 1. Rates of male and female patients recruited in randomised, placebo-controlled trials conducted to evaluate the efficacy of AD medications.




The drug think

Are we appropriate for everyone?









The depth of gluteal fat varies between men and women but the length of the injection needle does not vary. In women, the rate of success of IM injections is lower than in men (Soliman et al., 2018).

Grazie

Gracias



Danke

Thanks

ありがとうございました

Спасибо

<u>Conclusion</u> <u>Medicine's gender revolution is mandatory to</u> <u>reach equity</u>

to make this revolution it is necessary:

- a) The underrepresentation of women meaning that the "normality of women" is still unknown thus it is necessary that single governments fund strategic plans to bridge this gap. These studies should be multidisciplinary and intersectorial.
- b) The knowledge of "normality" are necessary to have drugs and medical devices that are more appropriate for all persons. In order to promote sex and based research it is necessary to adopt measures as happened in Europe for pediatric drugs namely a system of obligations and incentives for the companies